title: Idarubicin plus cytarabine as first-line treatment of acute nonlymphoblastic leukemia.
authors.affiliation: Instituto di Scienze Mediche, University of Milan, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Lambertenghi-Deliliers
authors.forename: C
authors.initials: C
authors.lastname: Annaloro
authors.forename: A
authors.initials: A
authors.lastname: Cortelezzi
authors.forename: M
authors.initials: M
authors.lastname: Cortellaro
authors.forename: A
authors.initials: A
authors.lastname: Della Volpe
authors.forename: A T
authors.initials: AT
authors.lastname: Maiolo
authors.forename: R
authors.initials: R
authors.lastname: Mozzana
authors.forename: E
authors.initials: E
authors.lastname: Pogliani
authors.forename: E
authors.initials: E
authors.lastname: Pozzoli
authors.forename: E E
authors.initials: EE
authors.lastname: Polli
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D012074:Remission Induction
chemical_list: D003561:Cytarabine; D015255:Idarubicin